We are committed to collaborating with leaders in the immuno-oncology field to realize the full potential of our T-SIGn® platform.
In addition to our internal pipeline development efforts, Akamis Bio is committed to collaborating with leaders in the immuno-oncology field from academia, research institutes, and the biopharma industry to realize the full potential of our tumor gene therapy platform. We have a number of ongoing collaborations which are focused on both novel T-SIGn® therapeutic development, as well as on the use of our existing pipeline programs in combination with other immuno-oncology modalities.
Akamis Bio is always seeking to identify potential partners with complementary technology to our T-SIGn® platform. In particular, we are interested in collaborating with companies working on immuno-oncology modalities with strong potential to synergize with our T-SIGn® therapeutics to deliver enhanced efficacy in the solid tumor setting (e.g., checkpoint inhibitors, antibody drug conjugates, bispecific T-cell engagers, and cell therapies).
Interested in collaborating with Akamis Bio?
Please visit our Contact Us page to start a dialog.
T-SIGn® therapeutics are viral vector based, tumor gene therapies which are capable of homing specifically to primary and metastatic solid tumors following intravenous delivery.
We have a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.
Our clinical studies are investigating the use of T-SIGn® therapeutics in the monotherapy setting, as well as in combination with other immuno-oncology agents to target specific solid tumor immune resistance mechanisms.